Chaudhary A, Khadka S, Dulal A, Adhikari R, Bhardwaj S, Pandey A
Ann Med Surg (Lond). 2024; 86(11):6693-6695.
PMID: 39525760
PMC: 11543217.
DOI: 10.1097/MS9.0000000000002197.
Elendu C, Osamuyi E, Afolayan I, Opara N, Chinedu-Anunaso N, Okoro C
Medicine (Baltimore). 2024; 103(30):e38890.
PMID: 39058828
PMC: 11272278.
DOI: 10.1097/MD.0000000000038890.
Hughes R
Eur J Neurol. 2024; 31(11):e16346.
PMID: 38752584
PMC: 11464409.
DOI: 10.1111/ene.16346.
Savithri Nandeesha S, Kasagga A, Hawrami C, Ricci E, Hailu K, Salib K
Cureus. 2024; 16(3):e57066.
PMID: 38681292
PMC: 11052558.
DOI: 10.7759/cureus.57066.
Bus S, de Haan R, Vermeulen M, van Schaik I, Eftimov F
Cochrane Database Syst Rev. 2024; 2:CD001797.
PMID: 38353301
PMC: 10865446.
DOI: 10.1002/14651858.CD001797.pub4.
Response to letter on European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barré syndrome.
van Doorn P, Van den Bergh P, Hadden R
Eur J Neurol. 2024; 31(4):e16230.
PMID: 38327088
PMC: 11235590.
DOI: 10.1111/ene.16230.
Plasmapheresis in the ICU.
Hussein G, Liu B, Yadav S, Warsame M, Jamil R, Surani S
Medicina (Kaunas). 2023; 59(12).
PMID: 38138254
PMC: 10744423.
DOI: 10.3390/medicina59122152.
Miller Fisher Syndrome Associated With COVID-19: A History of Molecular Mimicry and an Up-to-Date Review of the Literature.
Poyraz T
Cureus. 2023; 15(8):e43111.
PMID: 37692684
PMC: 10484161.
DOI: 10.7759/cureus.43111.
Early electrophysiological study variants and their relationship with clinical presentation and outcomes of patients with Guillain-Barré syndrome.
Khedr E, Shehab M, Mohamed M, Mohamed K
Sci Rep. 2023; 13(1):14000.
PMID: 37634022
PMC: 10460383.
DOI: 10.1038/s41598-023-41072-x.
Milestones in the history of neurocritical care.
Kollmar R, De Georgia M
Neurol Res Pract. 2023; 5(1):43.
PMID: 37559106
PMC: 10413505.
DOI: 10.1186/s42466-023-00271-7.
Progress in Guillain-Barré syndrome immunotherapy-A narrative review of new strategies in recent years.
Yao J, Zhou R, Liu Y, Lu Z
Hum Vaccin Immunother. 2023; 19(2):2215153.
PMID: 37278272
PMC: 10246479.
DOI: 10.1080/21645515.2023.2215153.
Research priorities for therapeutic plasma exchange in critically ill patients.
David S, Russell L, Castro P, van de Louw A, Zafrani L, Pirani T
Intensive Care Med Exp. 2023; 11(1):26.
PMID: 37150798
PMC: 10164453.
DOI: 10.1186/s40635-023-00510-w.
Principles of Therapeutic Apheresis in Neurological Disease.
Strasser E
Transfus Med Hemother. 2023; 50(2):88-97.
PMID: 37066058
PMC: 10091019.
DOI: 10.1159/000529463.
Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders.
Bo Chiang J, Arnold R, Dhanapalaratnam R, Markoulli M, Krishnan A
Pharmaceuticals (Basel). 2022; 15(5).
PMID: 35631433
PMC: 9144529.
DOI: 10.3390/ph15050607.
Post-COVID-19 Guillain-Barré Syndrome: A Case Report With Literature Review.
Kaeley N, Kabi A, Pillai A, Shankar T, Ameena M S S
Cureus. 2022; 14(1):e21246.
PMID: 35178309
PMC: 8842180.
DOI: 10.7759/cureus.21246.
Efficacy of therapies in the treatment of Guillain-Barre syndrome: A network meta-analysis.
Lin J, Gao Q, Xiao K, Tian D, Hu W, Han Z
Medicine (Baltimore). 2021; 100(41):e27351.
PMID: 34731107
PMC: 8519256.
DOI: 10.1097/MD.0000000000027351.
Intensive Care and Treatment of Severe Guillain-Barré Syndrome.
Shang P, Feng J, Wu W, Zhang H
Front Pharmacol. 2021; 12:608130.
PMID: 33995011
PMC: 8113987.
DOI: 10.3389/fphar.2021.608130.
Precision Medicine in Neurology: The Inspirational Paradigm of Complement Therapeutics.
Gavriilaki M, Kimiskidis V, Gavriilaki E
Pharmaceuticals (Basel). 2020; 13(11).
PMID: 33114553
PMC: 7693884.
DOI: 10.3390/ph13110341.
Post-infectious neurological disorders.
Blackburn K, Wang C
Ther Adv Neurol Disord. 2020; 13:1756286420952901.
PMID: 32944082
PMC: 7466892.
DOI: 10.1177/1756286420952901.
Asymmetric Lower Extremity Involvement and Facial Palsy: An Atypical Case of Guillain-Barre Syndrome.
Albawaliz A, Abdallah D, Seehra G, Elkafrawy A, Al-Shyoukh A
Cureus. 2020; 12(6):e8912.
PMID: 32742878
PMC: 7389875.
DOI: 10.7759/cureus.8912.